Elicio Therapeutics (NASDAQ:ELTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Elicio Therapeutics (NASDAQ:ELTX) from a strong sell rating to a sell rating in a research note published on Saturday.

Other research analysts also recently issued reports about the company. LADENBURG THALM/SH SH assumed coverage on Elicio Therapeutics in a research report on Thursday, June 18th. They set a “buy” rating and a $12.00 price objective for the company. JonesTrading cut Elicio Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, June 16th. B. Riley Financial assumed coverage on Elicio Therapeutics in a research report on Wednesday, June 10th. They set a “buy” rating and a $27.00 price target for the company. Weiss Ratings cut Elicio Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, July 29th. Finally, Rodman & Renshaw restated a “buy” rating on shares of Elicio Therapeutics in a research report on Monday, June 15th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $19.75.

Elicio Therapeutics Stock Performance

Shares of ELTX opened at $3.02 on Friday. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 1.20. The stock has a market cap of $57.65 million, a P/E ratio of -1.39 and a beta of 1.30. The company has a 50-day moving average of $4.24 and a two-hundred day moving average of $8.40. Elicio Therapeutics has a 12-month low of $2.66 and a 12-month high of $16.00.

Elicio Therapeutics (NASDAQ:ELTX) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.43) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.11. As a group, research analysts predict that Elicio Therapeutics will post -2.08 EPS for the current fiscal year.

Hedge Funds Weigh In On Elicio Therapeutics

A number of institutional investors have recently modified their holdings of ELTX. Bank of America Corp DE lifted its stake in shares of Elicio Therapeutics by 186.8% during the third quarter. Bank of America Corp DE now owns 3,585 shares of the company’s stock valued at $39,000 after buying an additional 2,335 shares during the period. Raymond James Financial Inc. purchased a new stake in Elicio Therapeutics in the 2nd quarter worth approximately $46,000. Deutsche Bank AG purchased a new stake in Elicio Therapeutics in the 2nd quarter worth approximately $49,000. Bank of New York Mellon Corp purchased a new position in shares of Elicio Therapeutics during the 2nd quarter worth $62,000. Finally, Summit Financial LLC purchased a new position in shares of Elicio Therapeutics during the 4th quarter worth $80,000. Institutional investors and hedge funds own 35.03% of the company’s stock.

About Elicio Therapeutics

Angion Biomedica Corp. is a late-stage biopharmaceutical company. It is focused on the discovery, development and commercialization of novel small molecule therapeutics to address acute organ injuries and fibrotic diseases. Angion Biomedica Corp. is based in UNIONDALE, N.Y.